AstraZeneca Plc (NASDAQ:AZN) released data from the ECHO Phase 3 trial of Calquence (acalabrutinib) plus bendamustine and rituximab compared to standard-of-care chemoimmunotherapy (bendamustine and rituximab) in adult patients at or over 65 years of age (n=635) with previously untreated mantle cell lymphoma (MCL). The data showed that the Calquence combo regime demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS). The results will be presented at the European Hematology Association 2024 Hybrid Congress. Also Read: AstraZeneca Targets Ambitious $80B In Total Revenue By 2030 Through Pipeline ...